The Stanly News and Press (Albemarle, NC)

State & National News

June 30, 2013

Fish-oil pills lure drugmakers though benefits remain unproven

Fish oil has been touted as useful for everything from growing hair to treating clinical depression. Now drug makers are stepping up their promotion of its benefits for treating heart disease.

AstraZeneca, Amarin and GlaxoSmithKline are betting the market for prescription fish-oil pills will follow the success of cholesterol-lowering drugs including Lipitor, once the world's best-selling medicine with revenue of $13 billion a year.

Heart disease remains the world's biggest killer, accounting for 30 percent of global deaths, even as statins and other treatments have become more widely used. Now that Lipitor and many other statins have cheaper, generic competitors, drugmakers are looking for new ways to tackle the array of conditions that can lead to heart disease, including coupling triglyceride treatments with existing cholesterol-lowering pills for a one-two punch.

 "The number of people with elevated triglyceride levels is rising rapidly across the world, due in part to the increasing prevalence of obesity and diabetes," AstraZeneca Chief Executive Officer Pascal Soriot said when he bought fish-oil pill maker Omthera Pharmaceuticals Inc. for $443 million last month. "There is a clear need for effective and convenient alternatives to some of the existing treatments."

Unlike capsules that can be bought in health-food stores, the drugmakers' products are available only with a prescription, are highly concentrated and undergo a several-step purification process approved by the U.S. Food and Drug Administration.

There's a hitch, however. Statins have been proven in studies to cut heart risk. The benefits of fish-oil pills are less certain. Though they target triglycerides, fatty substances in the blood that have been linked to a higher risk of heart attacks, little evidence exists that the pills prevent heart attacks.

"It's very unclear what role fatty acids play for cardiac patients," Mark Urman, a member of the American College of Cardiology Prevention Committee and practicing cardiologist at Cedars-Sinai Heart Institute, said in an interview. "The lab tests look better, but has it done the patient any good?"

Study results have been mixed. Japanese research on almost 19,000 people who took fish oil with a statin had a 19 percent lower risk of heart attacks, sudden cardiac death and other major coronary events, compared with those who took a statin alone.

A late-stage trial of Vascepa sponsored by Amarin found that it cut triglyceride levels by almost 22 percent at a 4-gram dose and 10 percent at a 2-gram dose without raising cholesterol levels in patients taking statins.

Other trials have shown little or no benefit. A study of more than 12,500 patients showed that a 1-gram daily dose of omega-3 fatty acids didn't prevent death or other cardiovascular events compared with placebo, according to an article in the New England Journal of Medicine in June 2012. And a review of data from 68,000 patients who took fish oil supplements over 24 years showed no reduction in risk of heart attack, stroke and death, the Journal of the American Medical Association said in September.

If cleared by regulators, AstraZeneca's Epanova would be the latest prescription pill to enter the market. It would bolster the London-based company's best-selling drug, a statin called Crestor, once it faces generic competition in 2016. While the drugmaker is still formulating its strategy, the Crestor sales team will pitch the product as an added benefit to the statin, said William Mongan, AstraZeneca's executive director of U.S. business development.

Amarin won U.S. approval to market Vascepa to people who have triglyceride levels of 500 milligrams per deciliter of blood or greater, a group of about 4 million people, according to the Dublin-based drugmaker. It's also seeking clearance to sell Vascepa for an additional 40 million people who have triglyceride levels between 200 milligrams and 500 milligrams, a "multi-billion dollar market opportunity."

Glaxo, whose Lovaza has brought in almost 2.5 billion pounds ($3.8 billion) in sales in the past five years, is more guarded about the market's prospects. In its 2012 annual report, the London-based drugmaker said the market had declined by 7 percent compared with 2011. Economic pressures have resulted in fewer doctor visits and reduced testing for conditions such as very high triglycerides that don't have any obvious symptoms, Glaxo said.

Without much evidence to support the claim that the pills cut heart risk, health-care purchasers remain skeptical of the benefits. Britain's medical spending watchdog, the National Institute for Health and Care Excellence, this month said it no longer recommends that heart attack survivors take fish-oil pills to prevent further heart attacks, citing their "minimal" benefit.

"It should be clear that they are not alternatives to statins," Cedars-Sinai's Urman said. He prescribes them predominately for patients who are in danger of developing pancreatitis, a painful inflammation of the pancreas caused by elevated triglyceride levels.

Vascepa has a long way to go to catch Lovaza. The drug had $4.3 million in sales between January and the end of April compared with $424.6 million for Lovaza, according to Symphony Health, a U.S. consulting firm. Amarin had to hire its own sales force after failing to find either a buyer for the company or a partner to help market Vascepa.

Amarin has fallen 60 percent in the last year and closed yesterday at $5.68, giving the drugmaker a market value of $854 million.

Analysts predict Lovaza sales will decline about 1.4 percent this year, according to the average of eight estimates compiled by Bloomberg.

"Do we need more preparations on the market? No," said Robert Eckel, director of the lipid clinic at the University of Colorado Hospital at the Anschutz Medical Campus in Aurora, Colo., and past president of the American Heart Association. "Do we have all of the answers about whether they are beneficial or not? No, we don't have those yet."

 

1
Text Only
State & National News
  • linda-ronstadt.jpg Obama had crush on First Lady of Rock

    Linda Ronstadt remained composed as she walked up to claim her National Medal of Arts at a White House ceremony Monday afternoon.

    July 29, 2014 1 Photo

  • Brother sues W.Va. senator over business loan

    FAIRMONT, W. Va. - U.S. Sen. Joe Manchin's brother claims he's owed $1.7 million that he loaned to keep a family carpet out of bankruptcy in the 1980s.

    July 28, 2014

  • CATS-DOGS281.jpg Where cats are more popular than dogs in the U.S.-and all over the world

    We all know there are only two types of people in the world: cat people and dog people. But data from market research firm Euromonitor suggest that these differences extend beyond individual preferences and to the realm of geopolitics: it turns out there are cat countries and dog countries, too.

    July 28, 2014 1 Photo

  • WORLD NEWS: Fast food comes to standstill in China

    BEIJING - The shortage of meat is the result of China's latest food scandal, in which a Shanghai supplier allegedly tackled the problem of expired meat by putting it in new packaging and shipping it to fast-food restaurants around the country

    July 28, 2014

  • Facebook continues moneymaking trend

    WASHINGTON - Facebook seems to have figured out - for now at least - the holy grail for all media right now: how to make money selling mobile ads.

    July 25, 2014

  • Arizona's prolonged lethal injection is fourth in U.S. this year

    NEW YORK - Arizona's execution of double-murderer Joseph Wood marked the fourth time this year that a state failed to dispatch a convict efficiently, according to the Constitution Project, a bipartisan legal group.

    July 25, 2014

  • N.C. Energy Policy Council Long Range Energy Generation and Renewable Energy Committee to meet

    RALEIGH – The North Carolina Energy Policy Council’s Long Range Energy Generation and Renewable Energy Committee will meet via conference call at 9 a.m. July 31.

    July 24, 2014

  • N.C. State University Turfgrass Field Day set for Aug. 13

    N.C. State University’s annual Turfgrass Field Day will be held in Raleigh at the Lake Wheeler Turfgrass Research Lab, Aug. 13, 8:30 a.m. - 2 p.m. One of the largest events of its kind in the country, the field day offers the industry and general public a chance to view the Turfgrass Program’s ongoing research trials and speak directly with N.C. State faculty and staff.

    July 24, 2014

  • NCSU Study: Urban Heat Boosts Some Pest Populations 200-Fold, Killing Red Maples

                New research from North Carolina State University shows that urban “heat islands” are slowly killing red maples in the southeastern United States. One factor is that researchers have found warmer temperatures increase the number of young produced by the gloomy scale insect – a significant tree pest – by 300 percent, which in turn leads to 200 times more adult gloomy scales on urban trees.

    July 23, 2014

  • An oncologist uses scorpion venom to locate cancer cells

    Olson, a pediatric oncologist and research scientist in Seattle, has developed a compound he calls Tumor Paint. When injected into a cancer patient, it seems to light up all the malignant cells so surgeons can easily locate and excise them.

    July 22, 2014

House Ads
Seasonal Content